Want to see MLEC full AI Analyst Report?
Top Page
Moolec Science
(NASDAQ:MLEC)
Select Model
Select Model
Rating:45Neutral
Price Target:
$8.00
▼(-10.41% Downside)
Action:Reiterated
Date:05/28/26
The score is primarily held down by weak financial performance—large losses, ongoing cash burn, and a significantly weakened capital structure with negative equity and elevated debt. Technicals also reflect a downtrend with negative momentum. Valuation signals are limited in the provided data, so they have a smaller, near-neutral impact.
Positive Factors
Revenue and gross margin improvement
A dramatic FY2025 revenue ramp and gross margin expansion to ~34% indicate meaningful commercialization traction for Moolec’s plant-produced ingredients. Sustained higher margins point to improving unit economics and potential scalable revenue streams as processing and customer adoption grow over the next months.
Negative Factors
Negative equity and high leverage
Material negative equity and roughly $246.9M of debt create a fragile capital structure that limits strategic flexibility. High leverage elevates refinancing and solvency risk, can constrain partnership or licensing negotiations, and increases the likelihood of equity dilution or costly financing over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and gross margin improvement
A dramatic FY2025 revenue ramp and gross margin expansion to ~34% indicate meaningful commercialization traction for Moolec’s plant-produced ingredients. Sustained higher margins point to improving unit economics and potential scalable revenue streams as processing and customer adoption grow over the next months.
Read all positive factors
Moolec Science (MLEC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.17M
Dividend YieldN/A
Average Volume (3M)209.37K
Price to Earnings (P/E)―
Beta (1Y)-0.15
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees103
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding726,118
10 Day Avg. Volume506,476
30 Day Avg. Volume209,369
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.12
P/FCF Ratio-1.35
Enterprise Value/Market Cap48.69
Enterprise Value/Revenue32.14
Enterprise Value/Gross Profit-393.66
Enterprise Value/Ebitda-48.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Moolec Science Business Overview & Revenue Model
Company Description
Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and...
How the Company Makes Money
Moolec Science makes money primarily by developing and commercializing genetically engineered crops that produce value-added food ingredients, then monetizing the resulting ingredients and/or the underlying technology. Key revenue streams include:...
Moolec Science Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
14
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2024 | Sep 2023 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.83M | 333.61M | 5.63M | 905.05K | 0.00 | 0.00 |
| Gross Profit | -639.50K | 114.01M | 472.58K | -143.31K | 0.00 | 0.00 |
| EBITDA | -5.21M | -69.01M | -6.16M | -51.74M | -3.65M | -13.80K |
| Net Income | -8.28M | -111.46M | -7.31M | -51.79M | -4.53M | -13.80K |
Balance Sheet | ||||||
| Total Assets | 31.38M | 204.71M | 34.79M | 24.05M | 5.69M | 138.59M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 9.02M | 5.39M | 2.83M | 1.08M | 337.60K |
| Total Debt | 22.09M | 246.88M | 14.68M | 2.65M | 125.00K | 125.00K |
| Total Liabilities | 28.58M | 287.58M | 27.97M | 13.95M | 4.09M | 4.51M |
| Stockholders Equity | 2.80M | -65.97M | 6.82M | 10.11M | 1.60M | 134.08M |
Cash Flow | ||||||
| Free Cash Flow | -6.12M | -30.10M | -9.49M | -7.69M | -1.89M | -8.80K |
| Operating Cash Flow | -5.70M | -24.45M | -9.33M | -7.51M | -1.89M | -8.80K |
| Investing Cash Flow | -270.17K | -35.99M | 134.87K | -2.34M | -138.00M | 0.00 |
| Financing Cash Flow | 5.95M | 13.07M | 11.71M | 11.28M | 139.05M | 14.49K |
Moolec Science Technical Analysis
Negative
8.93
Price Trends
7.78
Negative
8.51
Negative
8.17
Negative
Market Momentum
-0.15
Positive
40.20
Neutral
33.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLEC, the sentiment is Negative. The current price of 8.93 is above the 20-day moving average (MA) of 7.64, above the 50-day MA of 7.78, and above the 200-day MA of 8.17, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 40.20 is Neutral, neither overbought nor oversold. The STOCH value of 33.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLEC.
Moolec Science Risk Analysis
Moolec Science disclosed 3 risk factors in its most recent earnings report. Moolec Science reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Auditors Q2, 2024
2.
Directors and Senior Management Q2, 2024
3.
Advisors Q2, 2024
Moolec Science Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $5.17M | -0.03 | -174.68% | ― | ― | ― | |
42 Neutral | $7.15M | -0.15 | 261.84% | ― | -35.62% | 70.55% | |
42 Neutral | $4.48M | -0.08 | -386.72% | ― | -24.36% | 47.35% | |
| ― | $16.07M | -2.58 | -24.80% | ― | -4.23% | -17.96% | |
43 Neutral | $2.37M | -0.02 | ― | ― | ― | 76.55% |
* Healthcare Sector Average
MLEC
Moolec Science
7.00
-51.95
-88.13%
AIM
AIM ImmunoTech
0.27
-8.37
-96.84%
ENSC
Ensysce Biosciences
0.28
-1.88
-87.18%
CYCN
Cyclerion Therapeutics
3.66
0.64
21.19%
CLDI
Calidi Biotherapeutics
0.12
-7.27
-98.44%
Moolec Science Corporate Events
Moolec Science Faces Cayman Winding Up Petition Over Disputed Legal Fees
Jul 14, 2026
On July 8, 2026, Moolec Science SA reported receiving a winding up petition filed in the Grand Court of the Cayman Islands by Linklaters LLP over an alleged USD 2.3 million in unpaid legal fees tied to services procured under the company’s f...
Moolec Science Regains Nasdaq Compliance but Faces Year-Long Monitoring
Jun 2, 2026
On June 1, 2026, Moolec Science SA received notice from a Nasdaq Hearings Panel that it has regained compliance with all previously cited Nasdaq Capital Market continued listing requirements, including financial reporting, minimum bid price, and m...
Moolec Science Shareholders Approve 2025 Accounts and Board Slate at May 13 AGM
May 14, 2026
Moolec Science SA held its virtual Annual General Meeting of shareholders on May 13, 2026, with 71.24% of the 2,080,437 ordinary shares entitled to vote represented, establishing a valid quorum. Shareholders approved the consolidated financial sta...
Moolec Science Swings to Profit on Subsidiary Deconsolidation in Latest Interim Results
May 14, 2026
On May 13, 2026, Moolec Science SA filed a Form 6-K with the U.S. Securities and Exchange Commission for the month of May 2026, incorporating by reference unaudited interim condensed consolidated financial statements. The filing covers the company...
Moolec Science Regains Nasdaq Compliance After Strengthening Equity Base
May 13, 2026
On May 13, 2026, Moolec Science SA announced that it has regained compliance with all Nasdaq Capital Market continued listing requirements related to minimum stockholders’ equity within the remediation period granted by a Nasdaq Hearings Pan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.